Aktiesnakken — April 2021
-
God morgen.
-
Asien: Marke
derne har pil op men afventer inflationstal https://www.proinvestor.com/investornyt/673953/asien-markederne-har-pil-op-men-afventer-inflationstal -
USA/Rosengren: Ser markant økonomisk genopretning i år - GENT
https://www.proinvestor.com/investornyt/673952/usa-rosengren-ser-markant-okonomisk-genopretning-i-ar-gent -
DNB Markets @DNBMarkets
God morgenfra Norge
; Siden stengetid i Oslo i går er S&P Fut. +0.1%, Brent -0.9%, EQNR i USA -2.7%, FRO -0.8%, GOGL +0.5%, Nikkei i dag +1.1%, Hang Seng +1%. Fokus i dag; ACC, DNO, EQNR, FLYR, LSG, NAS, NHY, NORSE, TGS, SOHO, Kina handelsbalanse, OPEC -
Finwire News @Finwire
God morgon ifrån Sverige
! Dustin rapporterar sitt andra kvartal, kl 08.00. Telia handlas exklusive utdelning på 1 krona per aktie. Tysklands Zew-index släpps kl 11.00. -
Ugens vigtigste nøgletal kommer tirsdag eftermiddag i form af inflationstal fra USA, og frem til den begivenhed vil investorerne formentlig forholde sig relativt afventende.
Der er ikke set de store forskydninger i det amerikanske renter siden dansk børslukketid mandag, og derfor ventes de danske obligationsrenter at åbne tæt på uændret. https://www.proinvestor.com/investornyt/673957/obligationer-tendens-rolig-abning-i-vente-op-til-vigtigt-nogletal
-
Tirsdagens danske avisuddrag med Drilling, Ørsted og dansk økonomi https://www.proinvestor.com/investornyt/673958/tirsdagens-danske-avisuddrag-med-drilling-orsted-og-dansk-okonomi
-
God morgen fra Odense N
-
Aktier/tendens: Mærsk og Danske Bank kan få ekstra opmærksomhed
-
Matas: Den har haft et pænt run på det sidste -Er der nogen der har tid til at lave en TA på den? (Har aktien)
-
Pandora/SHB: Når pandemien falmer, skal salget vise sit værd: https://www.proinvestor.com/investornyt/673964/pandora-shb-nar-pandemien-falmer-skal-salget-vise-sit-vaerd
-
Jeg beder Rida fra mit analyseteam lave TA på Matas og Pandora.
-
Stort tak, Helge
-
Morning:)
-
Lundbeck- se her: Lundbeck shares fell more than 7% in early trading after decision to continue phase III clinical trial evaluating brexpiprazole for treatment of agitation in patients with Alzheimer's-type dementia.
• Lundbeck says completion of the trial is expected in the first half of 2022
• This means that the study didn't meet success stopping criteria at the interim analysis, Bank of America analysts said
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind